In an effort to expand its client base and comply with the
current regulatory needs,
Allscripts Healthcare Solutions
) announced the general availability of the latest Allscripts
Professional Electronic Health Record (EHR) 13.0. This new
physician practice solution is ONC 2014 certified, which supports
both Stage 1 and 2 Meaningful Use.
The advanced Allscripts Professional EHR 13.0 provides enhanced
billing competency and specialty-specific clinical content to
small and mid-sized physician practice groups. Moreover, it is
integrated with full patient portals viz. FollowMyHealth and
Intuit Patient Portals, necessary for meeting MU2 criteria.
Further, additional capabilities such as bi-directional
immunizations, InfoButton Technology, and Care Plans and Goals
help to improve user efficiency. In addition, the company
provides a number of services to update practitioners for all
stages of Meaningful Use.
Earlier in Aug 2013, along with the Professional 13.0, MDRX
received 2014 ONC HIT Certification for its Enterprise 11.4.1. In
the same month, the company announced the general availability of
the much-awaited Allscripts Wand 2.0. The Wand enables the
mobile healthcare professional to move between their desktop and
iPad for patient consultations and management. The result is a
streamlined workflow and faster access to data.
All new flagship products of the company are now generally
available. We believe that Allscripts has a significant base in
the fast-growing business of selling EHR to physician practices.
Allscript is one of the top vendors with the highest number of
complete EHR attestations.
MDRX is a leading clinical software and information solutions
provider for physicians. Its products are used widely across the
U.S. and Canada. Currently, the company serves approximately
180,000 physician practices, 1,500 hospitals, and 10,000
post-acute care facilities.
Allscripts Healthcare Solutions posted a significant fall in
adjusted earnings to $2.2 million or a penny per share in the
second quarter of 2013, from $23.1 million or 13 cents in the
comparable quarter of 2012. With this, earnings also missed the
Zacks Consensus Estimate of 7 cents for the reported quarter.
Revenues in the quarter ebbed 6.8% to $344.8 million, again
missing the Zacks Consensus Estimate of $358 million. The
decrease can be attributed to lower revenues generated from all
the operating segments.
While we avoid MDRX being a Zacks Rank #4 (Sell) stock, other
medical stocks that are performing well include
), both carrying a Zacks Rank #1 (Strong Buy), and
), carrying a Zacks Rank #2 (Buy).
AFFYMETRIX INC (AFFX): Free Stock Analysis
ALERE INC (ALR): Free Stock Analysis Report
ALLSCRIPTS HLTH (MDRX): Free Stock Analysis
MEDIDATA SOLUTN (MDSO): Free Stock Analysis
To read this article on Zacks.com click here.